August 5, 2026Journal of the American College of Cardiology
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Population
Patients with clinical ASCVD with or without comorbidities, primary prevention patients with LDL-C <190…
Design
Guideline
Authors
Discussion
Loading...
Member takes
Implication
This focused update provides revised clinical guidance on incorporating non-statin therapies, particularly ezetimibe and PCSK9 inhibitors, into the management of ASCVD risk based on new cardiovascular outcomes trial data.
Key Points
- The central aim is to update guidelines on non-statin therapies for lowering LDL-cholesterol in cardiovascular disease management.
- Review of existing literature and expert consensus on non-statin therapies.
- Evaluation of therapy outcomes on LDL-cholesterol levels.
- Synthesizing data to provide updated guidance for clinicians.
- Non-statin therapies effectively lower LDL-cholesterol levels, enhancing patient management.
- New strategies were recommended based on recent evidence and expert opinion.
Structured PICO
P
Population
Patients with clinical ASCVD with or without comorbidities, primary prevention patients with LDL-C <190 mg/dL with or without diabetes mellitus, and patients without ASCVD and LDL-C ≥190 mg/dL not due to secondary causes
I
Intervention
Non-statin therapies (ezetimibe, PCSK9 inhibitors, bile acid sequestrants) for LDL-cholesterol lowering
This focused update provides revised clinical guidance on incorporating non-statin therapies, particularly ezetimibe and PCSK9 inhibitors, into the management of ASCVD risk based on new cardiovascular outcomes trial data.
Cite This Study
Lloyd‐Jones et al. (2017) conducted a review in Atherosclerotic cardiovascular disease (ASCVD). Non-statin therapies (ezetimibe, PCSK9 inhibitors) was evaluated. The 2017 Expert Consensus Decision Pathway provides updated guidance on the use of ezetimibe and PCSK9 inhibitors in patients with clinical ASCVD with or without comorbidities on statin therapy.